Sites of non-CNS EMD and response to CAR T cells. (A) Patients with non-CNS EMD identifiable during retrospective central review. (B) Manifestations of non-CNS EMD (by percentage of patients) identified during central review of FDG PET/CT imaging from 38 patients screened across multiple early-phase trials at our institution over an 8-year period. (C) Non-CNS EMD in the cohort of 17 patients (18 infusions) who obtained serial FDG PET/CT images pre– and post–CAR T-cell infusion, with sites of non-CNS EMD exhibiting a CR to CAR T cells represented in blue. (D) Time to best response of medullary/non-CNS EMD in the cohort of 17 patients (18 infusions) who obtained serial FDG PET/CT images pre– and post–CAR T-cell infusion. (E) FDG PET/CT scans obtained pre– and post–CD19/22 CAR T-cell infusion showing a discrepant medullary/non-CNS EMD response. Patient 14 attained a medullary MRD-negative CR but exhibited non-CNS EMD PD, with new and worsening sites of non-CNS EMD identified in the adrenal gland, retroperitoneal lymph node, pancreas, and testes ∼1 month post–CAR T-cell infusion. (F) FDG PET/CT scans obtained pre– and post–CD19/22 CAR T-cell infusion showing a concurrent CR of medullary/non-CNS EMD at best response. Patient 13 presented to our institution with multifocal non-CNS EMD involving the lymph nodes, mediastinum, kidneys, and pancreas. NCI, National Cancer Institute; SD, stable disease.